In addition to building manufacturing infrastructure across multiple modalities, Resilience plans to offer its clients standardized protocols and consulting services that could help cut down on production...
Catamaran debuted Monday with a $42 million series A round to advance a pipeline of allogeneic CAR NK cell therapies that seed investor SV Health hopes can “democratize access to cell therapy.” SV’s Houman Ashrafian...
Umoja’s assembly of a three-step platform could allow the newly launched start-up to create off-the-shelf cell therapy cocktails that expand CAR T cells within patients to treat solid tumors or hematologic malignancies. Named for a...
LifeEDIT debuted with undisclosed funding from ElevateBio and former parent company AgBiome this week to develop novel RNA-guided nucleases and base editors that could offer broader genome access than...
InterVenn is tapping the glycoproteome for new markers for blood-based cancer diagnostics and using machine learning to accelerate the biomarker discovery process. The company announced Monday that...
Inipharm debuted Wednesday with $35 million in series A funding, a team of Mavupharma veterans and a small molecule portfolio targeting an enzyme that is upregulated across a handful of liver diseases. ...
Metagenomi is systematizing the search for new gene editing tools by scouring the genomes of bacteria in ecological samples. The company emerged from stealth Thursday with a $65 million series A round...
Cross-border biotech Kira is developing therapeutics for complement-mediated cancer and inflammatory and autoimmune diseases that address the mechanistic and PK challenges of targeting the complement pathway. Kira Pharmaceuticals Ltd. was founded in 2017 by Chairman, President...
CatalYm is targeting a lesser known immunosuppressant function of GDF15 to resensitize cancer patients to checkpoint blockade and enhance the ability of CAR T therapies to infiltrate solid tumors. The Munich-based biotech has raised €50 million...
Vaxxinity aims to disrupt the biologics market with a vaccine platform that replaces mAbs for chronic disease by inducing patients’ immune systems to manufacture therapeutic antibodies in vivo. But...
IgGenix is pairing single-cell sequencing with antibody engineering to create a new class of food allergy therapies that selectively suppresses allergen-triggered immunity while sidestepping the risky steps of desensitizing immunotherapy. The company launched in August with...
With $56 million in fresh funding from a crossover syndicate, newly launched Longboard will develop three neuroscience programs spun out from Arena that share familiar targets with therapies previously developed by the parent company. The...
A VC syndicate that backed IFM and serial dealmaker Gary Glick has launched precision oncology start-up Scorpion, where Glick will be president and CEO, with $108 million in series A funding. Scorpion...
SparingVision thinks its neuroprotective AAV therapy could benefit all retinitis pigmentosa patients, including those missed by mutation-targeted gene replacement therapies like Luxturna. The Paris-based...
Be Biopharma launched Thursday with a $52 million series A round led by Atlas Venture and RA Capital and a platform to engineer B cells that could overcome the durability, safety and re-dosing challenges of existing cell...
